Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report - Obesity drugs have become an ...

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

The Lupus Research Alliance (LRA), through its Lupus Accelerating Breakthroughs Consortium (Lupus ABC)—a public-private ...

Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

More than two weeks after President Donald Trump said he would halt “all payments” to Colombia, there has not been any interruption to the assistance, even after the administration sanctioned the ...

Lab equipment maker Waters Corp raised its annual profit forecast on Tuesday, after beating third-quarter profit estimates on ...

China on Tuesday defended its growing cooperation with Venezuela, saying that its engagement with leader Nicolás Maduro’s government “constitutes normal cooperation between sovereign states” and is ...

Why hadn’t I been able to save my son? What biological mechanisms made him so relentlessly ill? Could more effective ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...